Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence

被引:1
|
作者
Bedini, Annalida [1 ]
Elisi, Gian Marco [2 ]
Fanini, Fabiola [1 ]
Retini, Michele [1 ]
Scalvini, Laura [2 ]
Pasquini, Silvia [3 ]
Contri, Chiara [4 ]
Varani, Katia [4 ]
Spadoni, Gilberto [1 ]
Mor, Marco [2 ]
Vincenzi, Fabrizio [4 ]
Rivara, Silvia [2 ]
机构
[1] Univ Urbino Carlo Bo, Dipartimento Sci Biomol, Urbino, Italy
[2] Univ Parma, Dipartimento Sci Alimenti & Farmaco, Parco Area Sci 27-A, I-44121 Parma, Italy
[3] Univ Ferrara, Dipartimento Sci Chim Farmaceut & Agr, Ferrara, Italy
[4] Univ Ferrara, Dipartimento Med Traslaz, Via Luigi Borsari 46, I-44121 Ferrara, Italy
关键词
2-iodomelatonin; binding kinetics; free-energy simulations; melatonin receptors; stereoselectivity; UCM1014; unbinding; MOLECULAR PHARMACOLOGY; MT1; RADIOLIGANDS; DYNAMICS; AGONISTS; PROFILE; MODELS;
D O I
10.1111/jpi.12941
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The labeled ligand commonly employed in competition binding studies for melatonin receptor ligands, 2-[125I]iodomelatonin, showed slow dissociation with different half-lives at the two receptor subtypes. This may affect the operational measures of affinity constants, which at short incubation times could not be obtained in equilibrium conditions, and structure-activity relationships, as the Ki values of tested ligands could depend on either interaction at the binding site or the dissociation path. To address these issues, the kinetic and saturation binding parameters of 2-[125I]iodomelatonin as well as the competition constants for a series of representative ligands were measured at a short (2 h) and a long (20 h) incubation time. Concurrently, we simulated by molecular modeling the dissociation path of 2-iodomelatonin from MT1 and MT2 receptors and investigated the role of interactions at the binding site on the stereoselectivity observed for the enantiomers of the subtype-selective ligand UCM1014. We found that equilibrium conditions for 2-[125I]iodomelatonin binding can be reached only with long incubation times, particularly for the MT2 receptor subtype, for which a time of 20 h approximates this condition. On the other hand, measured Ki values for a set of ligands including agonists, antagonists, nonselective, and subtype-selective compounds were not significantly affected by the length of incubation, suggesting that structure-activity relationships based on data collected at shorter time reflect different interactions at the binding site. Molecular modeling simulations evidenced that the slower dissociation of 2-iodomelatonin from the MT2 receptor can be related to the restricted mobility of a gatekeeper tyrosine along a lipophilic path from the binding site to the membrane bilayer. The enantiomers of the potent, MT2-selective agonist UCM1014 were separately synthesized and tested. Molecular dynamics simulations of the receptor-ligand complexes provided an explanation for their stereoselectivity as due to the preference shown by the eutomer at the binding site for the most abundant axial conformation adopted by the ligand in solution. These results suggest that, despite the slow-binding kinetics occurring for the labeled ligand, affinity measures at shorter incubation times give robust results consistent with known structure-activity relationships and with interactions taken at the receptor binding site.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants
    Laffeber, Charlie
    de Koning, Kelly
    Kanaar, Roland
    Lebbink, Joyce H. G.
    JOURNAL OF MOLECULAR BIOLOGY, 2021, 433 (15)
  • [22] An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis
    Agarwal, Shivangi
    Verma, Ekta
    Kumar, Vivek
    Lall, Namrita
    Sau, Samaresh
    Iyer, Arun K.
    Kashaw, Sushil K.
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2018, 83 : 17 - 32
  • [23] PROBING THE BINDING DOMAIN OF THE NK2 RECEPTOR WITH FLUORESCENT LIGANDS - EVIDENCE THAT HEPTAPEPTIDE AGONISTS AND ANTAGONISTS BIND DIFFERENTLY
    TURCATTI, G
    VOGEL, H
    CHOLLET, A
    BIOCHEMISTRY, 1995, 34 (12) : 3972 - 3980
  • [24] PROBING THE BINDING DOMAIN OF THE NK2 RECEPTOR WITH FLUORESCENT LIGANDS - EVIDENCE THAT HEPTAPEPTIDE AGONISTS AND ANTAGONISTS BIND DIFFERENTLY
    TURCATTI, G
    VOGEL, H
    CHOLLET, A
    PROTEIN ENGINEERING, 1995, 8 : 115 - 115
  • [26] Search for β2 Adrenergic Receptor Ligands by Virtual Screening via Grid Computing and Investigation of Binding Modes by Docking and Molecular Dynamics Simulations
    Bai, Qifeng
    Shao, Yonghua
    Pan, Dabo
    Zhang, Yang
    Liu, Huanxiang
    Yao, Xiaojun
    PLOS ONE, 2014, 9 (09):
  • [27] Simulations of the estrogen receptor ligand-binding domain: Affinity of natural ligands and xenoestrogens. (vol 43, pg 4599, 2000)
    Oostenbrink, BC
    Pitera, JW
    van Lipzig, MMH
    Meerman, JHN
    van Gunsteren, WF
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (07) : 1124 - 1124
  • [28] Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice: evidence that CGS 21680 binds to A1 receptors in hippocampus
    Linda Halldner
    Luisa V. Lopes
    Elisabetta Daré
    Karin Lindström
    Björn Johansson
    Catherine Ledent
    Rodrigo A. Cunha
    Bertil B. Fredholm
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370 : 270 - 278
  • [29] Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice:: evidence that CGS 21680 binds to A1 receptors in hippocampus
    Halldner, L
    Lopes, LV
    Daré, E
    Lindström, K
    Johansson, B
    Ledent, C
    Cunha, RA
    Fredholm, BB
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 370 (04) : 270 - 278
  • [30] Nudicauline and elatine as potent norditerpenoid ligands at rat neuronal alpha-bungarotoxin binding sites: Importance of the 2-(methylsuccinimido)benzoyl moiety for neuronal nicotinic acetylcholine receptor binding
    Hardick, DJ
    Blagbrough, IS
    Cooper, G
    Potter, BVL
    Critchley, T
    Wonnacott, S
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (24) : 4860 - 4866